Answers are grounded in this paper and cite their sources.
In patients with high-risk early breast cancer, cytotoxic chemotherapy is a crucial component of treatment for all disease subtypes.1 Regimens containing an anthracycline and a taxane are the most effective in reducing the risk of recurrence and death in patients with early breast cancer.2 With the availability of effective supportive treatments including granulocyte colony-stimulating factor (G-CSF), several trials provided evidence that shortening the interval between cycles, i.e. administering such cytotoxic therapy in a dose-dense fashion, would further increase the efficacy of chemotherapy.
No takes yet. Share an insight, caveat, or question.
Lambertini et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: